Live L. crispatus cells demonstrated the ability to strongly reduce the adherence of invading yeast cells in all types of assays, the most powerful being the competition modality in which adherence was decreases by 58% compared to the control. The purified EPS only inhibited yeast adhesiveness if pre-incubated with vaginal cells before the addition of C. albicans, whereas it was not efficient in competing or displacing yeast cells. As is known, human defensins, short cysteine-rich cationic proteins, are key components of the innate immune system. The inducible human beta-defensins

are antimicrobial peptides with a broad spectrum of antibacterial and antifungal www.selleckchem.com/products/LY2603618-IC-83.html activity. Human beta-defensin 2 (HBD-2) is primarily produced by epithelial cells. The peptide is highly inducible due to various stimuli and has a broad spectrum antimicrobial activity that is cidal for Candida. It was interesting to observe that the pre-treatment of vaginal epithelial cells with EPS induced a high expression of the antimicrobial peptide HBD-2 against C. albicans. The up-regulation of HBD-2 might represent

a further mechanism of host protection against Candida infections. Overall these data indicate that this molecule is at least in part responsible of the impairment Romidepsin in vitro of C. albicans adhesion to vaginal cells, thus also demonstrating that it has a main role in the beneficial effect of L. crispatus L1 as a natural, probiotic, microbicide for vaginal health.

In the light of the information above it is not surprising that L. crispatus L1 synthesizes a mannan polysaccharide that closely resembles the carbohydrate part of mannoproteins and protein bound-polysaccharides excreted by C. albicans. In our opinion, this is a an important step towards the comprehension of the molecular mechanisms at the basis of the probiotic effect of L. crispatus ssp. Conclusions The present work describes the identification of a new human isolate named L. crispatus L1 and its characterization in order to demonstrate that it meets some of the criteria that identify probiotic strains, such as the ability to produce high titers of lactic acid and H2O2. In view of its potential application Meloxicam as oral vaginal probiotic, simulated digestion treatments were performed demonstrating its suitability for oral administration. Growth optimization was initially analysed in shake flasks and following microfiltration experiments allowed reaching high yields of extremely viable biomass, a key prerequisite for probiotic preparations. The characterization of the structure of the EPS produced by L. crispatus L1 showed a similarity with surface molecules produced by C. albicans and the inhibition of the adherence of this yeast to vaginal cells in the presence of live L. crispatus L1 further CYC202 mouse suggested an important role of this bacterium as a promoter of vaginal health. These achievements underlie the potential of L.